GlaxoSmithKline Logo
GB00BN7SWP63
A3DMB5
GLAXF

GlaxoSmithKline

Caricamento quotazioni...

Previsioni

Non sono disponibili dati degli analisti per questa azienda.


  • FDA places GSK drug Jemperli on priority review

    The US drug regulator FDA is giving priority review to GSK’s colorectal cancer drug Jemperli (dostarlimab) and has set a review deadline through February. Jemperli also qualifies for the priority voucher program, which can shorten the approval process. GSK expects the drug could make chemotherapy, radiation and surgery unnecessary for some patients; the company also reported approval of Hibsago in Japan for chronic hepatitis B. GSK’s stock traded slightly weaker during the session. » Altro su finanzen.net


  • GSK appoints Philips CEO Roy Jakobs to the board of directors

    GSK has appointed Roy Jakobs, currently CEO of Royal Philips, effective Sunday as an independent, non-executive member of the board. Jakobs, CEO of Philips since 2022 and with the company since 2010, will receive the usual annual fee of £122,258 and must hold shares worth twice that amount. The appointment was recommended by the nomination and corporate governance committee; after the decision the board has 13 members. » Altro su de.investing.com


  • Nuvalent reaches record high at $123.7 — GSK takeover offer at $124 per share

    Nuvalent shares climbed to an all-time high of $123.7 and are only 1% below the 52-week high after investors showed confidence in the biotech. GSK has made a $10.6 billion takeover offer ($124 per share) for Nuvalent’s oncology assets, including candidates Zidesamtinib and Neladalkib. Valuation checks suggest the stock may be trading above its fair value, and analysts such as UBS and Bernstein have adjusted their ratings/price targets after the takeover news to neutral/market perform and $124, respectively. Despite high liquidity relative to debt, Nuvalent remains unprofitable as investors monitor further developments. » Altro su de.investing.com

Nel 2026, GlaxoSmithKline ha già distribuito +0,59 di dividendi. L'ultimo pagamento è avvenuto a luglio.

Dati finanziari dell'azienda

Nell'ultimo trimestre, GlaxoSmithKline ha registrato ricavi pari a +9,76Mld e un utile netto di +504,95M
(EUR) giu 2026
YoY
Ricavi +9,76Mld 4,93%
Utile lordo +7,36Mld 8,49%
Utile netto +504,95M 69,96%
EBITDA +3,02Mld 19,72%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
+88,01Mld
Numero di azioni
4,01Mld
Massimo/minimo a 52 settimane
+27,04 - +16,31
Rendimento da dividendo
+3,49%
Dividendi TTM
+0,77
Beta
0,3
Rapporto P/E
+15,88
Rapporto PEG
+0,37
Rapporto P/B
+4,33
Rapporto P/S
+2,30

Profilo aziendale

GSK plc ist zusammen mit seinen Tochtergesellschaften in der Erforschung, Entwicklung, Herstellung und Vermarktung von pharmazeutischen Produkten, Impfstoffen, rezeptfreien Medikamenten und gesundheitsbezogenen Konsumgütern im Vereinigten Königreich, den Vereinigten Staaten und international tätig. Das Unternehmen ist in vier Segmenten tätig: Pharmazeutika, Pharmazeutische Forschung und Entwicklung, Impfstoffe und Consumer Healthcare. Das Unternehmen bietet pharmazeutische Produkte an, die Medikamente in den therapeutischen Bereichen Atemwegserkrankungen, HIV, Immunentzündungen, Onkologie, antivirale Mittel, zentrales Nervensystem, kardiovaskuläre und urogenitale Erkrankungen, Stoffwechselerkrankungen, antibakterielle Mittel und Dermatologie umfassen. Darüber hinaus bietet das Unternehmen Gesundheitsprodukte für Verbraucher in den Kategorien Wellness, Mundgesundheit, Ernährung und Hautgesundheit an. Das Unternehmen bietet seine Consumer-Healthcare-Produkte in Form von Nasensprays, Tabletten, Sirup, Lutschtabletten, Kaugummi und transdermalen Pflastern, Kapseln, Säuglingssirup, flüssig abgefüllten Suspensionen, Tüchern, Gelen, Brausen, Zahnpasten, Zahnbürsten, Mundspülungen, Prothesenklebern und -reinigern, topischen Cremes und arzneimittelfreien Pflastern, Lippenbalsam, Gummibärchen und Kauartikeln an. Das Unternehmen hat Kooperationsvereinbarungen mit 23andMe, Lyell Immunopharma, Inc, Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc, Alector, Inc und CureVac AG sowie eine strategische Partnerschaft mit IDEAYA Biosciences, Inc und Vir Biotechnology, Inc. Das Unternehmen war früher unter dem Namen GlaxoSmithKline plc bekannt und änderte im Mai 2022 seinen Namen in GSK plc. GSK plc wurde 1715 gegründet und hat seinen Hauptsitz in Brentford, Vereinigtes Königreich.

Nome
GlaxoSmithKline
CEO
Luke Victor Miels
Sede centrale London, gl
Regno Unito
Sito web
Settore
Sanità
Industria
Prodotti farmaceutici
Quotazione in borsa
01/07/1988
Dipendenti 66.841

Simboli di borsa

Borsa Simbolo
Pnk
GLAXF
London Stock Exchange
GSK.L
XETRA
GS71.DE
Frankfurt
GS71.F
Düsseldorf
GS71.DU
Hamburg
GS71.HM
London
GSK.L
SIX
GSK.SW
München
GS71.MU
🍪

Parqet  usa i cookie. Scopri di più